Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Manages pain severe enough to require an opioid analgesic. Sold as Dilaudid-Hp, Dilaudid, Palladone, Exalgo, Hydromorphone Hydrochloride. Every FDA application for this active ingredient: 7 branded and 23 generic.
As of Nov 16, 2026, FDA lists 30 applications for Hydromorphone Hydrochloride (sold as Dilaudid-Hp, Dilaudid, Palladone and others), first approved Jan 11, 1984, with 1 new use approved and 0 published complete response letters.
First approved: Jan 11, 1984
Applications: 30
New uses approved: 1
Complete response letters: 0
Medicare spending, 2025: $4.1M
First approved in Japan: Mar 30, 2017
Shortage: Current
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Hydromorphone ER
Part D
$3.9M
-15%
2,108
Dilaudid
Part D
$139K
-60%
84
Medicaid Spending
What state Medicaid programs paid pharmacies in 2025, before rebates, by product name; see every drug
Hydromorphone
$16.7M for 449,067 prescriptions, -59% on 2024
Dilaudid
$9.5M for 142,010 prescriptions, -60% on 2024
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
Hydromorphone 1 mg/ml solution: $0.234 per MLGeneric · -21% in a year
Hydromorphone 10 mg/ml vial: $2.57 per MLGeneric · new this year
Hydromorphone 2 mg tablet: $0.171 per unitGeneric · +2% in a year
Hydromorphone 2 mg/ml vial: $2.74 per MLGeneric · -1% in a year
Hydromorphone 4 mg tablet: $0.220 per unitGeneric · +15% in a year
Hydromorphone 5 MG/5 ml soln: $0.234 per MLGeneric · -21% in a year
Hydromorphone 50 MG/5 ml vial: $2.57 per MLGeneric · new this year
Hydromorphone 500 MG/50 ml vial: $2.57 per MLGeneric · new this year
Hydromorphone 500 MG/50 ml vl: $2.57 per MLGeneric · new this year
Hydromorphone 8 mg tablet: $0.549 per unitGeneric · -2% in a year
Hydromorphone hcl er 12 mg tab: $10.58 per unitGeneric · +0% in a year
Hydromorphone hcl er 16 mg tab: $12.38 per unitGeneric · +29% in a year
Adverse Event Reports (FAERS)
Cases reported to FDA naming this drug as the primary suspect, 2025 Q4 to 2026 Q3. A report does not show the drug caused the event.
Vomiting (38), Drug ineffective (33), Pain (33), Dyspnoea (27), Pneumonia (26), Drug hypersensitivity (25), Toxicity to various agents (23), Nausea (21), Off label use (21), Malaise (20)
First approved in Japan 399 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
Naruvein, new approvalDrugs with a new route of administration indicated for management of moderate to severe pain in various types of cancer. · Daiichi Sankyo Propharma Co., Ltd. · Jan 19, 2018
Narusus, new ingredientDrugs with a new active ingredient indicated for management of moderate to severe pain in various types of cancer. · Daiichi Sankyo Propharma Co., Ltd. · Mar 30, 2017
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA